AVEO Pharmaceuticals (AVEO) Stock Price, News & Analysis

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) announced its quarterly earnings data on Monday, November, 8th. The biopharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.36) by $0.06. The biopharmaceutical company had revenue of $15.17 million for the quarter, compared to the consensus estimate of $14.29 million. AVEO Pharmaceuticals had a negative net margin of 30.79% and a negative trailing twelve-month return on equity of 81.66%. During the same period in the prior year, the company posted ($0.33) earnings per share.

Shares of AVEO Pharmaceuticals reverse split on Thursday, February 20th 2020. The 1-10 reverse split was announced on Wednesday, February 19th 2020. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, February 19th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

4 employees have rated AVEO Pharmaceuticals Chief Executive Officer Tuan Ha-Ngoc on Glassdoor.com. Tuan Ha-Ngoc has an approval rating of 61% among the company's employees. This puts Tuan Ha-Ngoc in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 48.0% of employees surveyed would recommend working at AVEO Pharmaceuticals to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other AVEO Pharmaceuticals investors own include Exelixis (EXEL), Micron Technology (MU), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO), OPKO Health (OPK), Novavax (NVAX), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), Synergy Pharmaceuticals (SGYP) and NVIDIA (NVDA).